News
Incyte builds GvHD presence with Niktimvo approval
The FDA has approved Incyte's axatilimab as a treatment for chronic graft-versus-host disease (GvHD), making it a companion to the company's Jakafi for the disorder.
Tuesday 5 November 2024
